Dar Bioscience Inc recorded a cumulative net loss of $-11 million during 12 month ending in the second quarter 2026.
The Healthcare sector has seen employees of 146 other companies achieving higher income per employee. While income per employee total ranking has improved so far to 3484, from total ranking in previous quarter at 4049.

What is Income per Employee Ratio?

Select the Comparisons :

None ▼

Select the Ratio:

Net Income per Employee▼

None ▼

Net Income per Employee▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

DARE Net Income per Employee	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter
Y / Y Net Income Change	-	-	-	-	-
Net Income per Employee (TTM) $	-457,798	-500,869	-558,303	-667,131	-714,620
DARE's Total Ranking	# 3484	# 4049	# 3763	# 3897	# 2606
Seq. Net Income Change	-	-	-	-	-

DARE Company Profile >> Back to DARE Efficiency Comparisons >> Compare DARE Net Income per Employee to its Competitors

DARE Net Income per Employee Company Ranking
Within:	No.
Major Pharmaceutical Preparations Industry	# 147
Healthcare Sector	# 459
Overall Market	# 3484

Net Income per Employee Statistics
High	Average	Low
$ -9,323	$ -986,531	$ -1,902,833
(Mar 31 2025)		(Jun 30 2016)

News about Dar Bioscience Inc Income per employee

Dar Bioscience's $22 Million Non-Dilutive Financing Empowers Revolutionary Advancements in Women's Health

Dar Bioscience, a renowned pharmaceutical company specializing in women s health, has recently announced a significant achievement in securing a whopping $22 million in non-dilutive strategic royalty financing. This fresh injection of capital is set to bolster the company s commitment to advancing their Phase 3 first-in-category women s health product candidates through key catalysts, ultimately revolutionizing the landscape of women s healthcare.
The expansive capital injection marks a pivotal moment in Dar Bioscience s journey, as it enables the company to achieve its strategic objectives without diluting its existing shareholders equity. This non-dilutive financing represents a concerted effort to deliver innovative solutions for women in need, while also ensuring the growth and sustainability of the company. With this influx of funds, Dar Bioscience can accelerate the development and commercialization of its product candidates and provide transformative advancements to women s healthcare worldwide.

Dar Bioscience Announces Grant Funding Installment to Support Further Development of Novel Contraceptive Technology DARE-LARC1

Dar Biosciences, a renowned biotechnology company, has recently made waves in the medical community with its groundbreaking DARE-LARC1 platform technology. This innovative technology has not only shown promising results in transforming women s health but also in treating a wide range of diseases.
The DARE-LARC1 platform technology developed by Dare Biosciences has attracted significant attention due tilizing a unique approach to drug delivery. This revolutionary platform technology enables precise and targeted delivery of therapeutic agents to specific areas within the body, resulting in enhanced efficacy and reduced side effects. Additionally, the technology offers the potential for sustained release of medications over an extended period, providing long-lasting benefits to patients.

Dar Bioscience Receives Funding Award from NIH to Advance Groundbreaking Treatment for Preterm Birth

Dar Bioscience Inc, a leading pharmaceutical company, is developing a groundbreaking treatment called DARE-PTB1 to mitigate the risk of preterm birth. Currently, there are no FDA-approved treatment options available for this condition. Preterm birth, defined as giving birth before completing 37 weeks of gestation, poses numerous health risks for both the baby and the mother.
According to recent financial reports, Dar Bioscience Inc has recorded a significant cumulative net loss of $-41 million during the 12-month period ending in the third quarter of 2023. However, despite this financial setback, the company remains committed to advancing DARE-PTB1 and bringing a potential solution to women facing the risks associated with preterm birth.

Companies with similar Income per Employee for 12 month ending Jun 30 2026, within Healthcare Sector

Income per Employee

Income 12 month ending Jun 30 2026

Number of Employees Jun 30 2026

Date modified: 2026-09-03T11:42:10+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.